Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Use of Antiemetic Agents in Acute Gastroenteritis 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesPhase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer
Journal of Cancer Research & Clinical Oncology, 10/01/09
Li YH et al. – XELOX is a highly effective first–line treatment for Chinese mCRC patients. The response rate, TTP, and overall survival of patients treated with this regimen are similar to those treated with FU/leucovorin/oxaliplatin.
Related Articles
trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II
Cancer Causes and Control, 10/28/09
Relevance Score: 88%
Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study
Journal of Clinical Oncology, 10/02/09
Relevance Score: 88%
The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6
Gut, 11/09/09
Relevance Score: 87%
Extended lymph node dissection in colorectal cancer surgery. Reliability and reproducibility in assessments of operative reports
International Journal of Colorectal Disease, 11/02/09
Relevance Score: 87%
Improving colon cancer screening rates in primary care: a pilot study emphasising the role of the medical assistant
Quality & Safety in Health Care, 11/02/09
Relevance Score: 87%
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance
Journal of Clinical Oncology, 12/18/09
Survivin: a potential prognostic marker and chemoradiotherapeutic target for colorectal cancer
Irish Journal of Medical Science, 12/18/09
Application of a stress and coping model to positive and negative adjustment outcomes in colorectal cancer caregiving
Psycho-Oncology, 12/18/09
Sponsor
Article Search
Sponsor
Sponsor